CC
PRQR icon

Centiva Capital’s ProQR Therapeutics PRQR Stock Holding History

Centiva Capital’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-23,160
Closed -$37.5K – 2009
2023
Q2 		$37.5K Buy
+23,160
New +$45.2K ﹤0.01% 1518

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $544M AUM 72.49% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $47.2M AUM 32.31% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centiva Capital's PRQR Position: Q3 2023 in Review

Centiva Capital sold out of ProQR Therapeutics (PRQR) in Q3 2023, closing a stake of 23,160 shares — an estimated $37.5K sold.

Centiva Capital first reported a position in PRQR in Q2 2023 and held it in 1 quarter. The position peaked at $37.5K in Q2 2023. 46 funds tracked by Wall St. Rank hold PRQR as of Q3 2023.

  • Centiva Capital reported no remaining ProQR Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Centiva Capital sold 23,160 ProQR Therapeutics shares in Q3 2023, an estimated $37.5K.
  • Centiva Capital first reported a position in ProQR Therapeutics in Q2 2023 and held it in 1 quarter.
  • Centiva Capital's ProQR Therapeutics position peaked at $37.5K in Q2 2023.
  • 46 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q3 2023.

Based on Centiva Capital's 13F filing for Q3 2023, filed 14 Nov 2023.